Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 14/20 | 0.60 |
| ▸ | AKR1C2 | P52895 | 14/20 | 0.60 |
| ▸ | APP | P05067 | 4/20 | 0.51 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.48 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.48 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.48 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.48 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.48 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.48 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.43 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.43 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1201561 | 0.93 | AKR1C3 (0.56) | AKR1C3AKR1C2APPPSEN1PSEN2 | |
| SCHEMBL1201758 | 0.90 | APP (0.52) | AKR1C3AKR1C2APPPSEN1PSEN2 | |
| SCHEMBL1201838 | 0.87 | PSEN1 (0.50) | AKR1C3AKR1C2APPPSEN1PSEN2 | |
| SCHEMBL1202253 | 0.87 | PSEN1 (0.62) | AKR1C3AKR1C2APPPSEN1PSEN2 | |
| SCHEMBL1203318 | 0.85 | APP (0.57) | AKR1C3AKR1C2APPPSEN1PSEN2 | |
| SCHEMBL1203206 | 0.84 | PSEN1 (0.47) | AKR1C3AKR1C2APPPSEN1PSEN2 | |
| SCHEMBL1201706 | 0.84 | PSEN1 (0.47) | AKR1C3AKR1C2APPPSEN1PSEN2 | |
| SCHEMBL1202763 | 0.83 | APP (0.58) | AKR1C3AKR1C2APPPSEN1PSEN2 | |
| SCHEMBL1202565 | 0.83 | APP (0.51) | AKR1C3AKR1C2APPPSEN1PSEN2 | |
| SCHEMBL1203188 | 0.83 | PSEN1 (0.44) | AKR1C3AKR1C2APPPSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140187786-A1 | 1,3,4-TRISUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20110040094-A1 | 1,3,4-TRISUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| WO-2009036428-A2 | 1,3,4-TRISUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110040094-A1 | 1,3,4-TRISUBSTITUTED BENZENES | BACE1, BACE2, PSEN1 | AKR1C3 3717/4885AKR1C2 3410/4885APP 4/4885 |
| US-20140187786-A1 | 1,3,4-TRISUBSTITUTED BENZENES | BACE1, BACE2, PSEN1 | AKR1C3 3717/4885AKR1C2 3410/4885APP 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.